2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-107730
    NPY5RA-972 439861-56-0 98.99%
    NPY5RA-972 is an orally active, central nervous system (CNS) penetrating, potent and selective NPY Y5 receptor antagonist that prevents feeding driven by activation of this receptor.
    NPY5RA-972
  • HY-107731
    SF 11 443292-81-7 98.76%
    SF 11 is a potent and brain penetrant neuropeptide Y Y2 receptor antagonist (IC50=199 nM). Antidepressant-like activity.
    SF 11
  • HY-107748
    5'-Guanidinonaltrindole hydrochloride 351183-88-5 98.65%
    5'-Guanidinonaltrindole (5'-GNTI) hydrochloride is a highly selective and potent κ-opioid receptor antagonist with a Ki of 0.18 nM for human κ-opioid receptor.
    5'-Guanidinonaltrindole hydrochloride
  • HY-10792A
    Eplivanserin (mixture) 130581-13-4 99.68%
    Eplivanserin mixture (SR-46349 mixture) is a selective serotonin reuptake inhibitor and a 5-HT2A receptor antagonist, extracted from patent WO 2005/002578 A1.
    Eplivanserin (mixture)
  • HY-108069
    Iptakalim hydrochloride 642407-63-4 98.0%
    Iptakalim hydrochloride, a lipophilic para-amino compound, is a novel ATP-sensitive potassium channel (KATP) opener, as well as an α4β2-containing nicotinic acetylcholine receptor (nAChR) antagonist.
    Iptakalim hydrochloride
  • HY-108237
    Naxagolide 88058-88-2 99.81%
    Naxagolide ((+)-PHNO; Dopazinol) is a potent dopamine D2 (Dopamine Receptor) agonist. Naxagolide has the potential for the research of parkinson's disease (PD).
    Naxagolide
  • HY-108589
    PNU 37883 hydrochloride 57568-80-6 99.66%
    PNU 37883 hydrochloride (PNU 37883A) is a selective vascular ATP-sensitive potassium (Kir6, KATP) channels blocker. PNU 37883 hydrochloride has diuretic effects with specific binding in kidney and vascular smooth muscle rather than in brain or pancreatic beta cells.
    PNU 37883 hydrochloride
  • HY-109112
    Brilaroxazine 1239729-06-6 98.82%
    Brilaroxazine (RP5603) is a potent and orally active multimodal dopamine (DA)/serotonin (5-HT) modulator. Brilaroxazine is a partial agonist of dopamine (DA) D2, D3, and D4 receptors, 5-HT1A (Ki=1.5 nM) and 5-HT2A (Ki=2.5 nM), and has antagonist activity at 5-HT2B (Ki=0.19 nM), and 5-HT7 (Ki=2.7 nM) receptors. Brilaroxazine is an atypical antipsychotic agent, and has the potential to improve cognitive impairments in neuropsychiatric and neurological diseases in vivo.
    Brilaroxazine
  • HY-110146
    XAP044 196928-50-4 99.99%
    XAP044 is a potent and selective antagonist of mGlu7. The metabotropic glutamate receptor subtype 7 (mGlu7) is an important presynaptic regulator of neurotransmission in the mammalian CNS. XAP044 demonstrates good brain exposure and wide spectrum anti-stress and antidepressant- and anxiolytic-like efficacy in rodent behavioral paradigms.
    XAP044
  • HY-110168
    NS 9283 913830-15-6 98.15%
    NS9283 is a positive positive allosteric modulator of (α4)3(β2)2 nicotinic ACh receptors. NS9283 can be used in a series of neurological conditions such as attention deficit hyperactivity disorder (ADHD), schizophrenia, Parkinson's disease and Alzheimer's disease.
    NS 9283
  • HY-110199
    TC-I 2014 1221349-53-6 ≥99.0%
    TC-I 2014 (compound 5) is a potent and orally active Benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonist, with IC50 values of 0.8 nM, 3.0 nM and 4.4 nM for canine, human and rat channels respectively. TC-I 2014 exhibits antiallodynic properties in pain models.
    TC-I 2014
  • HY-111130
    Methapyrilene 91-80-5 99.66%
    Methapyrilene is a histamine antagonist, a pyridine chemical with anticholinergic activity. Methapyrilene can cause target organ-specific epigenetic alterations, such as a decrease in DNA methylation levels. Methapyrilene induces hepatocellular carcinoma in rats.
    Methapyrilene
  • HY-111527
    PPZ2 896203-18-2 99.92%
    PPZ2 is a diacylglycerol (DAG)-activated TRPC3/TRPC6/TRPC7 channel activator with activity in promoting neuronal development and survival. PPZ2 activates recombinant TRPC3/TRPC6/TRPC7 channels in a dose-dependent manner without affecting other TRPC channels. PPZ2 elicits cation currents and calcium ion (Ca(2+)) influx in cultured central neurons. PPZ2 is able to induce BDNF-like neurite outgrowth and neuroprotection, an effect that disappears after TRPC3/TRPC6/TRPC7 knockdown or inhibition. PPZ2 also increases the activation of the calcium-dependent transcription factor cAMP response element binding protein. The effects of PPZ2 suggest that calcium signaling mediated by activation of DAG-activated TRPC channels plays an important role in its neurotrophic effects.
    PPZ2
  • HY-111928
    5,7-Dimethoxyluteolin 90363-40-9 99.47%
    5,7-Dimethoxyluteolin, a 5,7-dimethylluteolin derivative, is a dopamine transporter (DAT) activator with an EC50 of 3.417 μM.
    5,7-Dimethoxyluteolin
  • HY-112340
    CB1 antagonist 4 1253641-65-4 98.00%
    CB1 antagonist 4 (compound 8) is a selective cannabinoid receptor 1 (CB1) inverse agonist with an IC50 of 8.5 nM for human CB1. CB1 antagonist 4 shows selective for CB1 over CB2 receptors (IC50 of 604.9 nM). CB1 antagonist 4 inhibits GTP binding to CB1-overexpressing cell membranes with an EC50 of 18.5 nM.
    CB1 antagonist 4
  • HY-112412
    PDGFR Tyrosine kinase-IN-1 205254-94-0 99.07%
    PDGFR Tyrosine kinase-IN-1, a multikinase inhibitor, inhibits PDGFR, EGFR, FGFR, PKA, and PKC, respectively. PDGFR Tyrosine kinase-IN-1 can be used for the research of amyotrophic lateral sclerosis.
    PDGFR Tyrosine kinase-IN-1
  • HY-112482
    ABT-702 214697-26-4 99.61%
    ABT-702 (Adenosine Kinase Inhibitor) is a potent, orally active, and selective adenosine kinase (AK) inhibitor with an IC50 of 1.7 nM. ABT-702 shows >1300-fold selectivity for AK over other biological targets, including cyclooxygenases-1 and -2. ABT-702 attenuates inflammation in diabetic retinopathy by increasing free adenosine levels. ABT-702 shows analgesic and anti-inflammatory effects in vivo. ABT-702 can be used for diabetic retinopathy research.
    ABT-702
  • HY-112659
    Lin28-let-7 antagonist 1 108825-65-6 99.43%
    Lin28-let-7 antagonist 1 (compound 1632) is a potent antagonist of Lin28/pre-let-7 interaction. Lin28-let-7 antagonist 1 inhibits Lin28A binding to pre-let-7a-2, with an IC50 of 8 μM. Lin28-let-7 antagonist 1 inhibits proliferation in human cancer cells.
    Lin28-let-7 antagonist 1
  • HY-113053
    Prostaglandin A1 14152-28-4 99.40%
    Prostaglandin A1 is a dehydration derivate of Prostaglandin E1. Prostaglandin A1 exhibits inhibitory activities against tumor growth, inflammation, virus replication, platelet aggregation and excitotoxin-induced neurons apoptosis.
    Prostaglandin A1
  • HY-113070
    Dihomo-γ-Linolenoyl Ethanolamide 150314-34-4 ≥99.0%
    Dihomo-γ-Linolenoyl Ethanolamide, an endocannabinoid, is a cannabinoid (CB) receptor agonist with Kis of 857 nM and 598 nM for human recombinant CB1 and CB2 receptors, respectively.
    Dihomo-γ-Linolenoyl Ethanolamide
Cat. No. Product Name / Synonyms Application Reactivity